CWBR - CohBar, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
United States

Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Pinchas CohenCo-Founder & Director58.33kN/A1957
Dr. Nir Yacov BarzilaiCo-Founder & Director58.33kN/A1956
Dr. John M. AmatrudaCo-Founder, Advisor, Consultant & Director67.5kN/A1945
Mr. Jeffrey F. Biunno CPA, MBACFO, Treasurer & Sec.272.95kN/A1966
Mr. Jon L. Stern M.B.A., MBACOO & Director309.9kN/A1955
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of diseases associated with aging and metabolic dysfunction. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular disease, and neurodegenerative disease, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel optimized analog of the MOTS-c mitochondrial-derived peptide for the treatment of NASH and obesity. The company was founded in 2007 and is headquartered in Menlo Park, California.

Corporate Governance

CohBar, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.